What is the difference between nintedanib and pirfenidone?

Nintedanib and pirfenidone (Pirfenidone) are anti-fibrotic drugs approved by regulatory agencies for the treatment of idiopathic pulmonary fibrosis and are available for clinical use worldwide. These drugs have been shown to reduce the rate of forced vital capacity decline and the risk of exacerbations in patients with idiopathic pulmonary fibrosis. Although they are both antifibrotic drugs used to treat specific conditions, they differ in some ways.

1. Mechanism of action: Nintedanib is a multi-target inhibitor that reduces the occurrence of pulmonary fibrosis by inhibiting multiple signaling pathways such as vascular endothelial growth factor receptor (VEGFR), fibronectin receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). Pirfenidone is a drug that regulates cytokines and can affect the production and signal transduction pathways of multiple cytokines such as transforming growth factor-beta (TGF-β), thereby reducing the degree of pulmonary fibrosis.

2. Indications: Nintedanib is suitable for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrosis related to atypical interstitial lung disease. Pirfenidone is indicated for the treatment of pulmonary fibrosis caused by idiopathic pulmonary fibrosis (IPF) and chronic renal insufficiency.

3. Dosage regimen: The recommended dose of nintedanib is 150 mg twice daily. The recommended dose of pirfenidone is 267 mg three times daily. The specific medication regimen should be used according to the doctor's recommendations.

4. Adverse reactions: Nintedanib may cause gastrointestinal reactions (such as nausea, vomiting, diarrhea), abnormal liver function and bleeding events. Pirfenidone may cause adverse reactions such as nausea, vomiting, loss of appetite, and rash.

The trade name of nintedanib is Vegat, and the trade name of pirfenidone is Asri; the use of any drug should be under the guidance of a doctor, because only a doctor can fully understand the condition and judge which drug is suitable for the patient.